1
|
Sharma M, Huber E, Arnesdotter E, Behrsing HP, Bettmann A, Brandwein D, Constant S, Date R, Deshpande A, Fabian E, Gupta A, Gutierrez R, Gutleb AC, Hargrove MM, Hollings M, Hutter V, Jarabek AM, Kaluzhny Y, Landsiedel R, Milchak L, Moyer RA, Murray JR, Page K, Patel M, Pearson SN, Petersen EJ, Reinke E, Roldan N, Roper C, Scaglione JB, Settivari RS, Stucki AO, Verstraelen S, Wallace JL, McCullough S, Clippinger AJ. Minimum information for reporting on the TEER (trans-epithelial/endothelial electrical resistance) assay (MIRTA). Arch Toxicol 2024:10.1007/s00204-024-03879-z. [PMID: 39365315 DOI: 10.1007/s00204-024-03879-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2024] [Accepted: 09/19/2024] [Indexed: 10/05/2024]
Abstract
Standard information reporting helps to ensure that assay conditions and data are consistently reported and to facilitate inter-laboratory comparisons. Here, we present recommendations on minimum information for reporting on the TEER (trans-epithelial/endothelial electrical resistance) assay (MIRTA). The TEER assay is extensively used to evaluate the health of an epithelial/endothelial cell culture model and as an indicator of the potential toxicity of a test substance. This publication is the result of an international collaboration─called the RespTox (Respiratory Toxicity) Collaborative─through which twelve laboratories shared their protocols for assessing the barrier function of respiratory epithelial cells using the TEER assay following exposure to substances. The protocols from each laboratory were reviewed to identify general steps for performing the TEER assay, interlaboratory differences between steps, the rationale for differences, whether these differences impact results or cross-laboratory comparisons between TEER measurements. While the MIRTA recommendations are focused on respiratory epithelial cell systems, these recommendations can be adapted for other cell systems that form barriers. The use of these recommendations will support data transparency and reproducibility, reduce challenges in data interpretation, enable cross-laboratory comparisons, help assess study quality, and facilitate the incorporation of the TEER assay into national and international testing guidance.
Collapse
Affiliation(s)
- Monita Sharma
- PETA Science Consortium International e.V., 70499, Stuttgart, Germany.
| | - Erin Huber
- Exposure and Protection, RTI International, 3040 East Cornwallis Road, Durham, NC, USA
| | - Emma Arnesdotter
- Environmental Research and Innovation (ERIN) Department, Luxemburg Institute of Science and Technology, 5 Avenue Des Hauts-Fourneaux, 4362, Esch-Sur-Alzette, Grand Duchy of Luxembourg
| | | | - Adam Bettmann
- PETA Science Consortium International e.V., 70499, Stuttgart, Germany
- , 3M Company, St. Paul, MN, 55144, USA
| | | | - Samuel Constant
- Epithelix Sàrl, Chemin Des Aulx 18, 1228, Plan-Les-Ouates, Switzerland
| | - Rahul Date
- Jai Research Foundation, N. H. 48, Near Daman-Ganga Bridge, Valvada, Gujarat, 396105, India
| | - Abhay Deshpande
- Jai Research Foundation, N. H. 48, Near Daman-Ganga Bridge, Valvada, Gujarat, 396105, India
| | - Eric Fabian
- BASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen, Germany
| | - Amit Gupta
- Life Science Research, Battelle Memorial Institute, Columbus, OH, 43201, USA
| | - Robert Gutierrez
- Materials Measurement Laboratory, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | - Arno C Gutleb
- Environmental Research and Innovation (ERIN) Department, Luxemburg Institute of Science and Technology, 5 Avenue Des Hauts-Fourneaux, 4362, Esch-Sur-Alzette, Grand Duchy of Luxembourg
| | - Marie M Hargrove
- Syngenta Crop Protection, 410 Swing Rd, Greensboro, NC, 27409, USA
| | - Michael Hollings
- Labcorp Early Development Laboratories Ltd., North Yorkshire, HG3 1PY, UK
| | - Victoria Hutter
- ImmuONE Ltd, Sycamore House, 16 Leyden Road, Stevenage, Herts, SG1 2BP, UK
- Centre for Topical Drug Delivery and Toxicology, University of Hertfordshire, College Lane Campus, Hatfield, Herts, AL10 9AB, UK
| | - Annie M Jarabek
- Center for Public Health and Environmental Assessment (CPHEA), Office of Research and Development, U.S. Environmental Protection Agency (EPA), Research Triangle Park, Washington, NC, 27711, USA
| | - Yulia Kaluzhny
- MatTek Life Sciences, Ashland, MA, 01721, USA
- InVitroTox Solutions Consulting, Newton, USA
| | - Robert Landsiedel
- BASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen, Germany
- Pharmacy, Pharmacology and Toxicology, Free University of Berlin, Berlin, Germany
| | - Lawrence Milchak
- , 3M Company, St. Paul, MN, 55144, USA
- Kimberly-Clark Corporation, Irving, USA
| | - Robert A Moyer
- Life Science Research, Battelle Memorial Institute, Columbus, OH, 43201, USA
| | - Jessica R Murray
- Center for Public Health and Environmental Assessment (CPHEA), Office of Research and Development, U.S. Environmental Protection Agency (EPA), Research Triangle Park, Washington, NC, 27711, USA
| | - Kathryn Page
- The Clorox Company, 4900 Johnson Dr, Pleasanton, CA, 94588, USA
| | - Manish Patel
- Jai Research Foundation, N. H. 48, Near Daman-Ganga Bridge, Valvada, Gujarat, 396105, India
| | - Stephanie N Pearson
- Life Science Research, Battelle Memorial Institute, Columbus, OH, 43201, USA
| | - Elijah J Petersen
- Materials Measurement Laboratory, National Institute of Standards and Technology (NIST), Gaithersburg, MD, 20899, USA
| | | | - Nuria Roldan
- PETA Science Consortium International e.V., 70499, Stuttgart, Germany
| | - Clive Roper
- Roper Toxicology Consulting Limited, Edinburgh, EH3 6AD, UK
| | | | | | - Andreas O Stucki
- PETA Science Consortium International e.V., 70499, Stuttgart, Germany
| | - Sandra Verstraelen
- Environmental Intelligence Unit, Flemish Institute for Technological Research (VITO), 2400, Mol, Belgium
| | - Joanne L Wallace
- Charles River Laboratories Edinburgh Ltd, Elphinstone Research Centre, Tranent, East Lothian, EH33 2NE, UK
| | - Shaun McCullough
- Exposure and Protection, RTI International, 3040 East Cornwallis Road, Durham, NC, USA
| | - Amy J Clippinger
- PETA Science Consortium International e.V., 70499, Stuttgart, Germany
| |
Collapse
|
2
|
Stucki AO, Sauer UG, Allen DG, Kleinstreuer NC, Perron MM, Yozzo KL, Lowit AB, Clippinger AJ. Differences in the anatomy and physiology of the human and rat respiratory tracts and impact on toxicological assessments. Regul Toxicol Pharmacol 2024; 150:105648. [PMID: 38772524 PMCID: PMC11198871 DOI: 10.1016/j.yrtph.2024.105648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2024] [Revised: 05/15/2024] [Accepted: 05/18/2024] [Indexed: 05/23/2024]
Abstract
Inhalation is a critical route through which substances can exert adverse effects in humans; therefore, it is important to characterize the potential effects that inhaled substances may have on the human respiratory tract by using fit for purpose, reliable, and human relevant testing tools. In regulatory toxicology testing, rats have primarily been used to assess the effects of inhaled substances as they-being mammals-share similarities in structure and function of the respiratory tract with humans. However, questions about inter-species differences impacting the predictability of human effects have surfaced. Disparities in macroscopic anatomy, microscopic anatomy, or physiology, such as breathing mode (e.g., nose-only versus oronasal breathing), airway structure (e.g., complexity of the nasal turbinates), cell types and location within the respiratory tract, and local metabolism may impact inhalation toxicity testing results. This review shows that these key differences describe uncertainty in the use of rat data to predict human effects and supports an opportunity to harness modern toxicology tools and a detailed understanding of the human respiratory tract to develop testing approaches grounded in human biology. Ultimately, as the regulatory purpose is protecting human health, there is a need for testing approaches based on human biology and mechanisms of toxicity.
Collapse
Affiliation(s)
| | - Ursula G Sauer
- Scientific Consultancy - Animal Welfare, Neubiberg, Germany
| | - David G Allen
- International Collaboration on Cosmetics Safety (ICCS), Mount Royal, NJ, USA
| | - Nicole C Kleinstreuer
- National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), National Institute of Environmental Health Sciences, NC, USA
| | - Monique M Perron
- US Environmental Protection Agency, Office of Pesticide Programs, Washington, DC, USA
| | - Krystle L Yozzo
- US Environmental Protection Agency, Office of Pesticide Programs, Washington, DC, USA
| | - Anna B Lowit
- US Environmental Protection Agency, Office of Pollution Prevention and Toxics, Washington, DC, USA
| | | |
Collapse
|
3
|
Foley B, Hopperstad K, Gamble J, Lynn SG, Thomas RS, Deisenroth C. Technical evaluation and standardization of the human thyroid microtissue assay. Toxicol Sci 2024; 199:89-107. [PMID: 38310358 DOI: 10.1093/toxsci/kfae014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2024] Open
Abstract
The success and sustainability of U.S. EPA efforts to reduce, refine, and replace in vivo animal testing depends on the ability to translate toxicokinetic and toxicodynamic data from in vitro and in silico new approach methods (NAMs) to human-relevant exposures and health outcomes. Organotypic culture models employing primary human cells enable consideration of human health effects and inter-individual variability but present significant challenges for test method standardization, transferability, and validation. Increasing confidence in the information provided by these in vitro NAMs requires setting appropriate performance standards and benchmarks, defined by the context of use, to consider human biology and mechanistic relevance without animal data. The human thyroid microtissue (hTMT) assay utilizes primary human thyrocytes to reproduce structural and functional features of the thyroid gland that enable testing for potential thyroid-disrupting chemicals. As a variable-donor assay platform, conventional principles for assay performance standardization need to be balanced with the ability to predict a range of human responses. The objectives of this study were to (1) define the technical parameters for optimal donor procurement, primary thyrocyte qualification, and performance in the hTMT assay, and (2) set benchmark ranges for reference chemical responses. Thyrocytes derived from a cohort of 32 demographically diverse euthyroid donors were characterized across a battery of endpoints to evaluate morphological and functional variability. Reference chemical responses were profiled to evaluate the range and chemical-specific variability of donor-dependent effects within the cohort. The data-informed minimum acceptance criteria for donor qualification and set benchmark parameters for method transfer proficiency testing and validation of assay performance.
Collapse
Affiliation(s)
- Briana Foley
- Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
| | - Kristen Hopperstad
- Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
| | - John Gamble
- Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
- Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee 37831, USA
| | - Scott G Lynn
- Office of Pesticide Programs, U.S. Environmental Protection Agency, Washington, District of Columbia 20460, USA
| | - Russell S Thomas
- Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
| | - Chad Deisenroth
- Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, USA
| |
Collapse
|
4
|
Moos P, Cheminant J, Adhikari U, Venosa A. Transcriptomic-based roadmap to the healthy and ozone-exposed lung. CURRENT OPINION IN TOXICOLOGY 2024; 37:100445. [PMID: 38187954 PMCID: PMC10769160 DOI: 10.1016/j.cotox.2023.100445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2024]
Abstract
The lung is constantly exposed to a myriad of exogenous stressors. Ground-level ozone represents a ubiquitous and extremely reactive anthropogenic toxicant, impacting the health of millions across the globe. While abundant, epidemiological, in vivo, and in vitro data focuses the ozone toxicity in individual cell types (e.g. epithelial type II, alveolar macrophages) or signaling pathways involved in the injury (e.g., akt, glutathione). When appropriately used, bulk and single cell RNA sequencing techniques have the potential to provide complete, and in certain cases unbiased, information of the molecular events taking place in the steady state and injured lung, and even capture the phenotypic diversity of neighboring cells. To this end, this review compiles information pertaining to the latest understanding of lung cell identity and activation in the steady state and ozone exposed lung. In addition, it discusses the value and benefits of multi-omics approaches and other tools developed to predict cell-cell communication and dissect spatial heterogeneity.
Collapse
Affiliation(s)
- Philip Moos
- Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
| | - Jenna Cheminant
- Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
| | - Ujjwal Adhikari
- Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
| | - Alessandro Venosa
- Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
| |
Collapse
|
5
|
Mallek NM, Martin EM, Dailey LA, McCullough SD. Liquid application dosing alters the physiology of air-liquid interface (ALI) primary human bronchial epithelial cell/lung fibroblast co-cultures and in vitro testing relevant endpoints. FRONTIERS IN TOXICOLOGY 2024; 5:1264331. [PMID: 38464699 PMCID: PMC10922929 DOI: 10.3389/ftox.2023.1264331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 12/14/2023] [Indexed: 03/12/2024] Open
Abstract
Differentiated primary human bronchial epithelial cell (dpHBEC) cultures grown under air-liquid interface (ALI) conditions exhibit key features of the human respiratory tract and are thus critical for respiratory research as well as efficacy and toxicity testing of inhaled substances (e.g., consumer products, industrial chemicals, and pharmaceuticals). Many inhalable substances (e.g., particles, aerosols, hydrophobic substances, reactive substances) have physiochemical properties that challenge their evaluation under ALI conditions in vitro. Evaluation of the effects of these methodologically challenging chemicals (MCCs) in vitro is typically conducted by "liquid application," involving the direct application of a solution containing the test substance to the apical, air-exposed surface of dpHBEC-ALI cultures. We report that the application of liquid to the apical surface of a dpHBEC-ALI co-culture model results in significant reprogramming of the dpHBEC transcriptome and biological pathway activity, alternative regulation of cellular signaling pathways, increased secretion of pro-inflammatory cytokines and growth factors, and decreased epithelial barrier integrity. Given the prevalence of liquid application in the delivery of test substances to ALI systems, understanding its effects provides critical infrastructure for the use of in vitro systems in respiratory research as well as in the safety and efficacy testing of inhalable substances.
Collapse
Affiliation(s)
- Nicholas M. Mallek
- Curriculum in Toxicology and Environmental Medicine, University of North Carolina, Chapel Hill, NC, United States
| | - Elizabeth M. Martin
- Epigenetics and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Durham, NC, United States
| | - Lisa A. Dailey
- Public Health and Integrated Toxicology Division, Center for Public Health and Environmental Assessment, United States Environmental Protection Agency, Chapel Hill, NC, United States
| | - Shaun D. McCullough
- Public Health and Integrated Toxicology Division, Center for Public Health and Environmental Assessment, United States Environmental Protection Agency, Chapel Hill, NC, United States
- Exposure and Protection, RTI International, Durham, NC, United States
| |
Collapse
|
6
|
To KT, Kleinstreuer N, Vasiliou V, Hogberg HT. New approach methodologies to address population variability and susceptibility. Hum Genomics 2023; 17:56. [PMID: 37381067 DOI: 10.1186/s40246-023-00502-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 06/13/2023] [Indexed: 06/30/2023] Open
Affiliation(s)
| | - Nicole Kleinstreuer
- NIH/NIEHS/DTT/NICEATM, RTP, Morrisville, NC, 27709, USA
- Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, 06520, USA
| | - Vasilis Vasiliou
- Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, 06520, USA
| | | |
Collapse
|
7
|
Travagli V, Iorio EL. The Biological and Molecular Action of Ozone and Its Derivatives: State-of-the-Art, Enhanced Scenarios, and Quality Insights. Int J Mol Sci 2023; 24:ijms24108465. [PMID: 37239818 DOI: 10.3390/ijms24108465] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 04/19/2023] [Accepted: 05/04/2023] [Indexed: 05/28/2023] Open
Abstract
The ultimate objective of this review is to encourage a multi-disciplinary and integrated methodological approach that, starting from the recognition of some current uncertainties, helps to deepen the molecular bases of ozone treatment effects on human and animal well-being and to optimize their performance in terms of reproducibility of results, quality, and safety. In fact, the common therapeutic treatments are normally documented by healthcare professionals' prescriptions. The same applies to medicinal gases (whose uses are based on their pharmacological effects) that are intended for patients for treatment, diagnostic, or preventive purposes and that have been produced and inspected in accordance with good manufacturing practices and pharmacopoeia monographs. On the contrary, it is the responsibility of healthcare professionals, who thoughtfully choose to use ozone as a medicinal product, to achieve the following objectives: (i) to understand the molecular basis of the mechanism of action; (ii) to adjust the treatment according to the clinical responses obtained in accordance with the principles of precision medicine and personalized therapy; (iii) to ensure all quality standards.
Collapse
Affiliation(s)
- Valter Travagli
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Viale Aldo Moro 2, 53100 Siena, Italy
| | - Eugenio Luigi Iorio
- International Observatory of Oxidative Stress, 84127 Salerno, Italy
- Campus Uberlândia, Universidade de Uberaba (UNIUBE), Uberlândia 38055-500, Brazil
| |
Collapse
|
8
|
Mallek NM, Martin EM, Dailey LA, McCullough SD. Liquid Application Dosing Alters the Physiology of Air-Liquid Interface Primary Bronchial Epithelial Cultures and In vitro Testing Relevant Endpoints. RESEARCH SQUARE 2023:rs.3.rs-2570280. [PMID: 36865279 PMCID: PMC9980280 DOI: 10.21203/rs.3.rs-2570280/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Differentiated Primary human bronchial epithelial cell (dpHBEC) cultures grown under air-liquid interface (ALI) conditions exhibit key features of the human respiratory tract and are thus critical for respiratory research as well as efficacy and toxicity testing of inhaled substances (e.g., consumer products, industrial chemicals, and pharmaceuticals). Many inhalable substances (e.g., particles, aerosols, hydrophobic substances, reactive substances) have physiochemical properties that challenge their evaluation under ALI conditions in vitro. Evaluation of the effects of these methodologically challenging chemicals (MCCs) in vitro is typically conducted by "liquid application," involving the direct application of a solution containing the test substance to the apical, air-exposed surface of dpHBEC-ALI cultures. We report that the application of liquid to the apical surface of a dpHBEC-ALI co-culture model results in significant reprogramming of the dpHBEC transcriptome and biological pathway activity, alternative regulation of cellular signaling pathways, increased secretion of pro-inflammatory cytokines and growth factors, and decreased epithelial barrier integrity. Given the prevalence of liquid application in the delivery of test substances to ALI systems, understanding its effects provides critical infrastructure for the use of in vitro systems in respiratory research as well as in the safety and efficacy testing of inhalable substances.
Collapse
|
9
|
Chapman F, Pour SJ, Wieczorek R, Trelles Sticken E, Budde J, Röwer K, Otte S, Mason E, Czekala L, Nahde T, O'Connell G, Simms L, Stevenson M. Twenty-eight day repeated exposure of human 3D bronchial epithelial model to heated tobacco aerosols indicates decreased toxicological responses compared to cigarette smoke. FRONTIERS IN TOXICOLOGY 2023; 5:1076752. [PMID: 36875887 PMCID: PMC9979258 DOI: 10.3389/ftox.2023.1076752] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 01/09/2023] [Indexed: 02/18/2023] Open
Abstract
Tobacco harm reduction (THR) involves providing adult smokers with potentially reduced harm modes of nicotine delivery as alternatives to smoking combustible cigarettes. Heated tobacco products (HTPs) form a category with THR potential due to their ability to deliver nicotine and flavours through heating, not burning, tobacco. By eliminating burning, heated tobacco does not produce smoke but an aerosol which contains fewer and lower levels of harmful chemicals compared to cigarette smoke. In this study we assessed the in vitro toxicological profiles of two prototype HTPs' aerosols compared to the 1R6F reference cigarette using the 3D human (bronchial) MucilAir™ model. To increase consumer relevance, whole aerosol/smoke exposures were delivered repeatedly across a 28 day period (16, 32, or 48 puffs per exposure). Cytotoxicity (LDH secretion), histology (Alcian Blue/H&E; Muc5AC; FoxJ1 staining), cilia active area and beat frequency and inflammatory marker (IL-6; IL-8; MMP-1; MMP-3; MMP-9; TNFα) levels were assessed. Diluted 1R6F smoke consistently induced greater and earlier effects compared to the prototype HTP aerosols across the endpoints, and in a puff dependent manner. Although some significant changes across the endpoints were induced by exposure to the HTPs, these were substantially less pronounced and less frequently observed, with apparent adaptive responses occurring over the experimental period. Furthermore, these differences between the two product categories were observed at a greater dilution (and generally lower nicotine delivery range) for 1R6F (1R6F smoke diluted 1/14, HTP aerosols diluted 1/2, with air). Overall, the findings demonstrate the THR potential of the prototype HTPs through demonstrated substantial reductions in toxicological outcomes in in vitro 3D human lung models.
Collapse
Affiliation(s)
| | | | | | | | | | - Karin Röwer
- Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany
| | - Sandra Otte
- Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany
| | | | | | - Thomas Nahde
- Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany
| | | | - Liam Simms
- Imperial Brands PLC, Bristol, United Kingdom
| | | |
Collapse
|
10
|
Moreau M, Fisher J, Andersen ME, Barnwell A, Corzine S, Ranade A, McMullen PD, Slattery SD. NAM-based Prediction of Point-of-contact Toxicity in the Lung: A Case Example With 1,3-dichloropropene. Toxicology 2022; 481:153340. [PMID: 36183849 DOI: 10.1016/j.tox.2022.153340] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 07/13/2022] [Accepted: 09/27/2022] [Indexed: 11/27/2022]
Abstract
Time, cost, ethical, and regulatory considerations surrounding in vivo testing methods render them insufficient to meet existing and future chemical safety testing demands. There is a need for the development of in vitro and in silico alternatives to replace traditional in vivo methods for inhalation toxicity assessment. Exposures of differentiated airway epithelial cultures to gases or aerosols at the air-liquid interface (ALI) can assess tissue responses and in vitro to in vivo extrapolation can align in vitro exposure levels with in-life exposures expected to give similar tissue exposures. Because the airway epithelium varies along its length, with various regions composed of different cell types, we have introduced a known toxic vapor to five human-derived, differentiated, in vitro airway epithelial cell culture models-MucilAir of nasal, tracheal, or bronchial origin, SmallAir, and EpiAlveolar-representing five regions of the airway epithelium-nasal, tracheal, bronchial, bronchiolar, and alveolar. We have monitored toxicity in these cultures 24hours after acute exposure using an assay for transepithelial conductance (for epithelial barrier integrity) and the lactate dehydrogenase (LDH) release assay (for cytotoxicity). Our vapor of choice in these experiments was 1,3-dichloropropene (1,3-DCP). Finally, we have developed an airway dosimetry model for 1,3-DCP vapor to predict in vivo external exposure scenarios that would produce toxic local tissue concentrations as determined by in vitro experiments. Measured in vitro points of departure (PoDs) for all tested cell culture models were similar. Calculated rat equivalent inhaled concentrations varied by model according to position of the modeled tissue within the airway, with nasal respiratory tissue being the most proximal and most sensitive tissue, and alveolar epithelium being the most distal and least sensitive tissue. These predictions are qualitatively in accordance with empirically determined in vivo PoDs. The predicted PoD concentrations were close to, but slightly higher than, PoDs determined by in vivo subchronic studies.
Collapse
Affiliation(s)
- Marjory Moreau
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA
| | - Jeff Fisher
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA
| | - Melvin E Andersen
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA
| | - Asayah Barnwell
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA
| | - Sage Corzine
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA
| | - Aarati Ranade
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA
| | - Patrick D McMullen
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA
| | - Scott D Slattery
- ScitoVation, LLC, 6 Davis Drive, Suite 146, Durham, North Carolina, 27709, USA.
| |
Collapse
|